Peter Hein

Dr. Peter Hein

Bayer AG
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2005 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PHPeter Hein
Peter Hein
MFMonika Frank
Monika Frank
CHCarsten Hoffmann
Carsten Hoffmann
MLMartin J Lohse
Martin J Lohse
MBMoritz Bünemann
Moritz Bünemann
The interaction of activated G protein‐coupled receptors with G proteins is a key event in signal transduction. Here, using a fluorescence resonance energy transfer (FRET)‐based assay, we measure directly and in living cells the interaction of YFP‐labeled α2A‐adrenergic receptors with CFP‐labeled G proteins. Upon agonist stimulation, a small, concentration‐dependent increase in FRET was observed. No specific basal FRET was detected in the absence of agonist. Kinetics of the onset of receptor/G protein interaction were <100 ms and depended on expression levels of Gα. Simultaneously recorded G protein‐regulated inwardly rectifying K+ channel currents revealed a maximal current response already at agonist concentrations producing submaximal FRET amplitudes. By analyzing FRET signals in the presence of a Gα mutant, which dissociates more slowly from activated receptors, it was demonstrated that only a fraction of wild‐type G proteins interacts with the activated receptor at any time. Our data suggest that α2A‐adrenergic receptors and G proteins interact by rapid collision coupling and indicate that there is no significant precoupling between these receptors and G proteins.

1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PHPeter Hein
Peter Hein
FRFrancesca Rochais
Francesca Rochais
CHCarsten Hoffmann
Carsten Hoffmann
SDSandra Dorsch
Sandra Dorsch
VNViacheslav O. Nikolaev
Viacheslav O. Nikolaev
MBMoritz Bünemann
Moritz Bünemann
To analyze individual steps of GS-linked signaling in intact cells, we used fluorescence resonance energy transfer (FRET)-based assays for receptor-G protein interaction, G protein activation, and cAMP effector activation. To do so, we developed a FRET-based sensor to directly monitor GS activation in living cells. This was done by coexpressing a Gαs mutant, in which a yellow fluorescent protein was inserted, together with cyan fluorescent protein-tagged Gβγ subunits and appropriate receptors in HEK293 cells. Together with assays for receptor activation and receptor-G protein interaction, it is possible to characterize large parts of the GS signaling cascade. When A2A-adenosine or β1-adrenergic receptors are coexpressed with GS in HEK293T cells, the receptor-GS interaction was on the same time scale as A2A receptor activation with a time constant of <50 ms. GS activation was markedly slower and around 450 ms with similar kinetics following activation of A2A- or β1-receptors. Taken together, our kinetic measurements demonstrate that the rate of GS activation limits initiation of GS-coupled receptor signaling.

1 March 2008 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MLMartin J. Lohse
Martin J. Lohse
VNViacheslav O. Nikolaev
Viacheslav O. Nikolaev
PHPeter Hein
Peter Hein
CHCarsten Hoffmann
Carsten Hoffmann
JVJean-Pierre Vilardaga
Jean-Pierre Vilardaga
MBMoritz Bünemann
Moritz Bünemann

1 March 2008 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MLM J Lohse
M J Lohse
PHPeter Hein
Peter Hein
CHC Hoffmann
C Hoffmann
VNV O Nikolaev
V O Nikolaev
JVJ‐P Vilardaga
J‐P Vilardaga
MBM Bünemann
M Bünemann

1 January 2004 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
TSTim Schneider
Tim Schneider
PHPeter Hein
Peter Hein
MMMartin C. Michel
Martin C. Michel
We have reexamined the muscarinic receptor subtype mediating carbachol-induced contraction of rat urinary bladder and investigated the role of phospholipase (PL)C, D, and A2 and of intra- and extracellular Ca2+ sources in this effect. Based on the nonsubtype-selective tolterodine, the highly M2 receptor-selective (R)-4-{2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl}-piperidine-1-carboxylic acid amide (Ro-320-6206), and the highly M3 receptor-selective darifenacin and 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP), contraction occurs via M3 receptors. Carbachol stimulated inositol phosphate formation in rat bladder slices, and this was abolished by the phospholipase C inhibitor 1-(6-[([17β]-3-methoxyestra-1,3,5[10]-trien-17-yl)-amino]hexyl)-1H-pyrrole-2,5-dione (U 73,122; 10 μM). Nevertheless, U 73,122 (1–10 μM) did not significantly affect carbachol-stimulated bladder contraction. Carbachol had only little effect on PLD activity in bladder slices, but the PLD inhibitor butan-1-ol, relative to its negative control butan-2-ol (0.3% each), caused detectable inhibition of carbachol-induced bladder contraction. The cytosolic PLA2 inhibitor arachidonyltrifluoromethyl ketone weakly inhibited carbachol-induced contraction at a concentration of 300 μM, but the cyclooxygenase inhibitor indomethacin (1–10 μM) remained without effect. The Ca2+ entry blocker nifedipine (10–100 nM) almost completely inhibited carbachol-induced bladder contraction. In contrast, 1-[β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole HCl (SKF 96,365; 10 μM), an inhibitor of store-operated Ca2+ channels, caused little inhibition. We conclude that carbachol-induced contraction of rat bladder largely depends on Ca2+ entry through nifedipine-sensitive channels and, perhaps, PLD, PLA2, and store-operated Ca2+ channels, whereas cyclooxygenase and, surprisingly, also PLC are not involved to a relevant extent.

30 July 2005 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
TSTim Schneider
Tim Schneider
PHPeter Hein
Peter Hein
MMMartina B. Michel-Reher
Martina B. Michel-Reher
MMMartin C. Michel
Martin C. Michel